{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:35Z","timestamp":1792790495950,"version":"4.5.0"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,15]]},"DOI":"10.2169\/internalmedicine.3008-19","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T18:02:57Z","timestamp":1566928977000},"page":"3557-3562","source":"Crossref","is-referenced-by-count":19,"title":["Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer"],"prefix":"10.2169","volume":"58","author":[{"given":"Satoshi","family":"Yamagata","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Takayasu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Asari","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Terui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Daimon","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895, 1992.","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704, 2008.","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297, 2002.","DOI":"10.1073\/pnas.192461099"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2: 662-673, 2013.","DOI":"10.1002\/cam4.106"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195-207, 2017.","DOI":"10.1038\/nrendo.2016.205"},{"key":"6","unstructured":"6. Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 360: k793, 2018."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28: 583-589, 2017.","DOI":"10.1093\/annonc\/mdw640"},{"key":"8","unstructured":"8. Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102: 2770-2780, 2017."},{"key":"9","unstructured":"9. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13: 211, 2015."},{"key":"10","unstructured":"10. Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther 8: 929-937, 2015."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24: T331-T347, 2017.","DOI":"10.1530\/ERC-17-0358"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mahzari M, Liu D, Arnaout A, Lochnan H. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes 8: 21-28, 2015.","DOI":"10.4137\/CMED.S22469"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Bellastella G, Maiorino MI, Bizzarro A, et al. Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary 19: 625-642, 2016.","DOI":"10.1007\/s11102-016-0736-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ishikawa M, Oashi K. Case of hypophysitis caused by nivolumab. J Dermatol 44: 109-110, 2016.","DOI":"10.1111\/1346-8138.13437"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J 63: 905-912, 2016.","DOI":"10.1507\/endocrj.EJ16-0161"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6: 230ra45, 2014.","DOI":"10.1126\/scitranslmed.3008002"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mei Y, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7: 76565-76576, 2016.","DOI":"10.18632\/oncotarget.12088"},{"key":"18","unstructured":"18. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5: 520, 2014."},{"key":"19","unstructured":"19. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101: 364-389, 2016."},{"key":"20","unstructured":"20. Fish HR, Chernow B, O'Brian JT. Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycemia: a review. Metabolism 35: 763-780, 1986."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sauter NP, Toni R, McLaughlin CD, Dyess EM, Kritzman J, Lechan RM. Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortin-derived peptides. J Clin Endocrinol Metab 70: 1391-1397, 1990.","DOI":"10.1210\/jcem-70-5-1391"},{"key":"22","unstructured":"22. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 88: 4193-4198, 2003."},{"key":"23","unstructured":"23. Maghnie M, Uga E, Temporini F, et al. Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic-pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol 152: 735-741, 2005."},{"key":"24","unstructured":"24. Merck & Co., Inc., Whitehouse Station (NJ). KEYTRUDA (Pembrolizumab) Prescribing Information [Internet]. [cited 2017 Dec 1]; Available from: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Otsubo K, Nakatomi K, Furukawa R, et al. Two cases of late onset secondary adrenal insufficiency after discontinuation of nivolumab. Ann Oncol 28: 3106-3107, 2017.","DOI":"10.1093\/annonc\/mdx497"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Boudjemaa A, Rousseau BG, Monnet I. Late-onset adrenal insufficiency more than 1 year after stopping pembrolizumab. J Thorac Oncol 13: e39-e40, 2018.","DOI":"10.1016\/j.jtho.2017.10.023"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016.","DOI":"10.1016\/j.ctrv.2016.02.001"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3008-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T22:42:04Z","timestamp":1576881724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3008-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,15]]},"references-count":27,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3008-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,15]]}}}